## United States Court of Appeals for the Federal Circuit

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

 $Plaintiffs ext{-}Appellants$ 

 $\mathbf{v}.$ 

ACTAVIS LABORATORIES UT, INC.,

Defendant-Appellee

-----

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

Plaintiffs-Appellants

 $\mathbf{v}_{\boldsymbol{\cdot}}$ 

MYLAN TECHNOLOGIES INC.,

Defendant-Appellee

2021-1924, 2021-2336

2021-1924, 2021-2000

Appeals from the United States District Court for the District of Delaware in Nos. 1:19-cv-00474-KAJ, 2:19-cv-00128-cr, Chief Judge Christina Reiss, Circuit Judge Kent A. Jordan.

**MANDATE** 

\_\_\_\_\_

In accordance with the judgment of this Court, entered April 12, 2023, and pursuant to Rule 41 of the Federal Rules of Appellate Procedure, the formal mandate is hereby issued.

FOR THE COURT

May 26, 2023 Date /s/ Peter R. Marksteiner Peter R. Marksteiner Clerk of Court